| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director
2 companies
Andrew Cheng is Director at VERA and has filed Form 4s across 2 companies. Andrew Cheng's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $537K at current prices.
The biggest single holding is VERA (~$537K) as Director.
Andrew Cheng has 12 Form 4 filings on record from August 2019 to August 2026, across 4 companies: Director at Damora Therapeutics (DMRA), 2026; Director at Vera Therapeutics (VERA), 2021–2026; President and CEO at AKRO, 2025, and 1 more.
The 27 reported transactions were 16 dispositions back to the company, 10 option or other derivative awards and 1 conversion.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria